Integra LifeSciences Corp. recalled 55,276 units of MEDIHONEY Calcium Alginate with Active Leptospermum Honey on January 16, 2026. The recall cites potential packaging failures that may compromise sterility. Affected products include model numbers 31012, 31022, and 31045.
Potential packaging failures, which could lead to a breach in the sterile barrier.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Integra LifeSciences Corp. (NeuroSciences) or your healthcare provider for instructions. Notification method: Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
This recall involves MEDIHONEY Calcium Alginate with Active Leptospermum Honey, model numbers 31012, 31022, and 31045. The products were distributed worldwide, including across multiple U.S. states such as Texas, Michigan, and Florida. The exact quantity recalled is 55,276 units.
The recall is due to potential packaging failures which could lead to a breach in the sterile barrier. This defect poses a high risk of infection for patients using the products for wound management.
There are no specific reports of injuries or incidents linked to this recall. The nature of the recall indicates a preventative measure against potential health risks.
Patients and healthcare providers should stop using the affected products immediately. They should follow the recall instructions provided by Integra LifeSciences Corp. for further guidance.
For further information, contact Integra LifeSciences Corp. at their designated customer service lines or through their website. The recall notification may be communicated through email, fax, letter, press releases, or phone calls.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.